spacer
home > > summer 2009 > the hard cell
PUBLICATIONS


The Hard Cell

Developing new compounds for pharmacological applications involves a series of well established steps, including the design of small molecules and their synthesis, testing compounds using in vitro methods, and the assessment of compound activity in vivo, employing animal and human trials. Notably, the cost of this process increases as a drug advances further along the process towards market. For a compound to advance, it must satisfy stringent criteria before the decision to invest further in its development is made. There is continual review of the drug development process within the pharmaceutical industry to introduce new approaches to develop compounds in more efficient and costeffective ways. It is important to have stringent tests in order to avoid investing in compounds that will fail later in the development process. The key is to identify when to abort research and development of a particular candidate, and to learn from the experience.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Stefan Przyborski is the founder and Chief Scientific Officer of Reinnervate, a spinout company from Durham University, which aims to develop new ways to manage the growth and function of cultured cells. Stefan also holds an academic position as Reader in Stem Cell Biology at Durham University. He has over 18 years’ experience in cell biology, has published more than 60 scientific papers and has filed several patents. More recently, he has developed multi-disciplinary approaches through collaborative projects with physical scientists to develop novel ways of solving biological problems.
spacer
Stefan Przyborski
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals

[Pamplona, November 26 2019] 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, a UK based Biotech company, to collaborate in the development of a novel anti-tumour treatment.
More info >>

White Papers

Bonfiglioli Engineering Headspace Gas Analysis Systems for Parenteral Manufacturing Processes: One Step Beyond Product Quality and Patient Safety

Bonfiglioli Engineering

This white paper presents the innovative solutions that Bonfiglioli Engineering has been developing in the field of HGA and their significant advantages over other existing systems.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement